Skip to main content

GSK: Can This Pharma Giant Sustain Its 5.2% Yield?

GlaxoSmithKline’s free cash flow has been up and down. Over the past three years, it has grown substantially, though this year, it is forecast to drop 18%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.